Sanofi SA
SAN: XPAR (FRA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€132.00 | Ghsvk | Vzlskcdf |
Sanofi: Acquisition of Inhibrx Yields Intriguing Rare Disease Drug INBRX-101 at a Reasonable Price
Sanofi’s announced acquisition of Inhibrx for just over $2 billion largely nets early-stage Alpha-1 antitrypsin deficiency (AATD) drug INBRX-101 at a reasonable price. We are not making any changes to our fair value estimate based on the deal, as the sales of INBRX-101 hold the potential to offset the costs. The drug helps develop Sanofi’s midstage pipeline, reinforcing the company’s wide moat.